Torgyán S, Wagner L, Neumann T, Pakuts B, Csányi M
Int J Clin Pharmacol Biopharm. 1979 Nov;17(11):439-41.
A double-blind cross-over clinical trial was performed to compare clinical effectiveness of indomethacin (3 x 25 mg/day) alone to that of a combination of indomethacin + sodium-salycylate (3 x 25 mg/day and 3 x 250 mg/day, respectively) in rheumatoid arthritis. It was established that enteral blood loss was significantly reduced by combined treatment as determined by Cr51 labelled erythrocytes in comparison to that after treatment with indomethacin alone. Therapeutic effect was maintained in both groups, no significant disparities were observed. Occurrence of subjective complaints was less frequent in the combined treatment group. It was concluded that the combined preparation consisting of indomethacin and sodium-salicylate has a favourable effect in rheumatoid arthritis.
进行了一项双盲交叉临床试验，以比较吲哚美辛（3×25毫克/天）单独使用与吲哚美辛+水杨酸钠联合使用（分别为3×25毫克/天和3×250毫克/天）在类风湿性关节炎中的临床疗效。结果表明，与单独使用吲哚美辛治疗后相比，联合治疗通过51铬标记红细胞测定可显著减少肠道失血。两组均维持治疗效果，未观察到显著差异。联合治疗组主观不适的发生率较低。得出结论，由吲哚美辛和水杨酸钠组成的联合制剂对类风湿性关节炎有良好疗效。
